Chemotherapy News and Research

Latest Chemotherapy News and Research

MRSA infection hVISA linked to mortality

A MRSA infection with a reduced susceptibility to the potent antibiotic drug vancomycin is linked to high mortality, according to a Henry Ford Hospital study.

12 Sep 2010

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc., today announced that it has unblinded the Phase 3 study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer) whose disease has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel.

10 Sep 2010

Koronis Pharmaceuticals to present KP-1461 clinical trial data at ICAAC Conference

Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced that clinical trial data demonstrating that the Company's lead HIV drug, KP-1461, resulted in increased HIV mutations consistent with the Viral Decay Acceleration mechanism will be featured in a late-breaker oral presentation by James Mullins, Ph.D., Professor of Microbiology and Medicine at the University of Washington, at the upcoming 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Boston, MA.

10 Sep 2010

Allos Therapeutics to present FOLOTYN trial results at ESMO Congress

Allos Therapeutics, Inc. today announced that results from the Phase 2b investigational trial of FOLOTYN (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented at the 35th European Society of Medical Oncology (ESMO) Congress

10 Sep 2010

DARA BioSciences presents KRN5500 study results at World Congress on Pain

DARA BioSciences announced today that it presented study results from its Phase 2 multicenter, placebo controlled, double-blind, randomized dose escalation study for KRN5500 at the 13th World Congress on Pain held recently in Montreal.

9 Sep 2010

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VELOUR clinical trial of aflibercept (VEGF Trap) in patients with metastatic colorectal cancer (mCRC) will continue to completion as planned, with no modifications due to efficacy or safety concerns. This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis.

9 Sep 2010

Hormone treatment with chemotherapy results in deadly side-effect in neuroblastoma children

Children given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect, according to a major international study published today (Tuesday) in the Journal of Clinical Oncology.

9 Sep 2010

Two genes linked to ovarian clear cell carcinoma

Scientists at the Johns Hopkins Kimmel Cancer Center have identified two genes whose mutations appear to be linked to ovarian clear cell carcinoma, one of the most aggressive forms of ovarian cancer. Clear cell carcinoma is generally resistant to standard therapy.

9 Sep 2010

Cachexia reduces function and changes muscle structure of heart in mice with colon cancer

The wasting disease associated with some cancers that is typically seen affecting skeletal muscles can also cause significant damage to the heart, new research in mice suggests.

9 Sep 2010

Scientists identify molecular marker to analyze chemotherapy response in breast cancer patients

A new predictive marker which could help doctors to decide whether breast cancer patients would benefit from chemotherapy has been identified by a team of scientists. The study, part-funded by Cancer Research UK and published in the British Journal of Cancer today (Wednesday), shows for the first time how this molecular marker has been singled out as an independent factor in examining a breast cancer patient's tumour.

9 Sep 2010

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, will deliver four poster presentations on its compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

9 Sep 2010

Micro-RNAs programmed cells can lead to malignant growth

Cancer becomes life threatening when tumor cells start leaving their primary site. They travel through the lymph and blood streams to other tissues where they grow into metastases. This transition to malignancy is associated with characteristic changes in the cancer cells. The activity of several genes is reprogrammed and, thus, the production of proteins anchoring cells to a tissue is reduced. On the other hand, the amount of surface markers which make a cancer cell mobile increases.

9 Sep 2010

CTTC's Calmare therapy effective against pain associated with chemotherapy-induced peripheral neuropathy

Competitive Technologies, Inc. announced today the publication of the detailed results from a study that shows the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTTC's Calmare® Pain Therapy Treatment

9 Sep 2010

Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

Tetraphase Pharmaceuticals, Inc., today announced that 12 poster presentations and an oral summary presentation on preclinical and clinical data for its lead drug candidate, TP-434, will be presented at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA, being held September 12 -15 at the Boston Convention and Exhibition Center.

9 Sep 2010

ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

9 Sep 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

Lack of data on best way to treat nausea and vomiting in children undergoing chemotherapy

Although nausea and vomiting are common in children undergoing chemotherapy, few quality studies identify absolutely the best way to prevent and treat this problem in kids, said Robert Phillips, M.D., lead author of a new Cochrane review. Phillips, a pediatric oncologist at St. James's Hospital in Leeds, England, said the main finding is the paucity of data that he and his colleagues uncovered.

8 Sep 2010

Gemcitabine does not improve survival compared with fluorouracil plus folinic acid in resected pancreatic cancer

Use of gemcitabine, a drug that can be effective in treating advanced and resected pancreatic cancer, did not result in improved overall survival after pancreatic cancer resection (surgical removal) compared to patients who received fluorouracil and folinic acid, another treatment regimen that has shown effectiveness, according to a study in the September 8 issue of JAMA.

8 Sep 2010

TransOral Robotic Surgery removes head and neck cancer tumors, while preserving speech

An incisionless robotic surgical procedure is offering patients a new option to remove certain head and neck cancer tumors without visible scarring, while preserving speech and the ability to eat.

8 Sep 2010

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Onyx Pharmaceuticals, Inc. today announced that it has entered into an exclusive agreement with Ono Pharmaceutical Co., Ltd. to develop and commercialize two compounds from Onyx's proteasome inhibitor development program, carfilzomib and ONX 0912. Under the terms of the agreement, Ono has exclusive rights to develop and commercialize both compounds for all oncology indications in Japan.

8 Sep 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

MRSA infection hVISA linked to mortality

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Koronis Pharmaceuticals to present KP-1461 clinical trial data at ICAAC Conference

Allos Therapeutics to present FOLOTYN trial results at ESMO Congress

DARA BioSciences presents KRN5500 study results at World Congress on Pain

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Hormone treatment with chemotherapy results in deadly side-effect in neuroblastoma children

Two genes linked to ovarian clear cell carcinoma

Cachexia reduces function and changes muscle structure of heart in mice with colon cancer

Scientists identify molecular marker to analyze chemotherapy response in breast cancer patients

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

Micro-RNAs programmed cells can lead to malignant growth

CTTC's Calmare therapy effective against pain associated with chemotherapy-induced peripheral neuropathy

Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Lack of data on best way to treat nausea and vomiting in children undergoing chemotherapy

Gemcitabine does not improve survival compared with fluorouracil plus folinic acid in resected pancreatic cancer

TransOral Robotic Surgery removes head and neck cancer tumors, while preserving speech

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in